Stock·NASDAQ·Healthcare
AstraZeneca (AZN)
- Market cap
- $263.72B
- P/E
- 25.42
- Dividend yield
- 1.87%
- Street target
- $208.00median of 12 analysts
- 52-week range
- $153.41 $212.71
AZN stock forecast today
Where AZN stands today, and what CleaRank Financial AI makes of it.
AZN at a glance
AstraZeneca (AZN): Buy, 64/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 50-day but below its 200-day moving average ($163.66 and $180.35).
- Earnings AZN beat estimates in 5 of the 6 reports in our data, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $54K and bought $11.7M over the last 18 months.
- Valuation P/E of 25.4 against 31.9 for the Healthcare sector: a discount to peers (-20%).
Figures as of October 27, 2026.
CleaRank Financial AI
AstraZeneca (AZN) carries a CleaRank rating of Buy and a model score of 64/100.
The analysts' outlook adds the most to that score: 9 of 12 analysts rate it a buy, and the median target is 22.3% above the price. The trend pulls the score down the most. The price is 5.71% below its 200-day average, and the 50-day average is 9.26% below the 200-day. The 50-day average is $163.66 and the 200-day is $180.35. Over the past year the price rose 1.15%.
Only on CleaRank
Figures we compute ourselves from AZN's own price, earnings and insider-filing history. Tap one to see it in context.
AZN stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
1/4Price above its 50-day average ›
The price of $170.05 is 3.9% above the 50-day simple moving average of $163.66.Price above its 200-day average ›
The price is 5.7% below the 200-day simple moving average of $180.35.50-day average above the 200-day ›
The 50-day average ($163.66) is 9.3% below the 200-day average ($180.35), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 28% of its 52-week range, between $153.41 and $212.71.
AZN share price
Pick a period: each tab shows how far AZN has moved over it, to the last close.
Today's trading
Where AZN sits inside today's range and its 52-week range.
AZN fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 25.42 is 20.3% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 4.33 is 27.5% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $10.4B on revenue of $61.4B, a net margin of 17.0%.Beat estimates in most recent reports ›
AZN beat the EPS estimate in 5 of the 6 reports in our data.Pays a dividend ›
The trailing dividend yield is 1.87%, or $3.18 a share a year.
Key statistics
The headline figures for AZN.
As of October 27, 2026, AZN trades at $170.05, with a market value of $263.72B, a P/E ratio of 25.42 and a dividend yield of 1.87%.
What the numbers say
CleaRank Financial AI's reading of AZN's valuation, growth and risks.
On earnings, AstraZeneca (AZN) is valued at 25.42 times, against a median of 31.9 for Healthcare: a discount to peers, with the P/E 20.3% below that median. On sales, the P/S of 4.33 compares with a sector median of 3.4, 27.4% above it. For scale, AZN carries trailing earnings of $6.69 a share.
In the latest quarter, against the same quarter a year earlier, revenue grew 6.40%, 1.7 percentage points slower than the sector median of 8.1%. Margins stand at a net margin of 17.02% and an operating margin of 23.46%. It generates a return on equity of 21.97%, above the sector median of 7.3%. Debt-to-equity of 0.64 and a trailing dividend yield of 1.87% ($3.18 a share a year) round out the fundamentals.
AZN beat expectations in its July 27, 2026 report by 5.60%, posting EPS of $1.32 against the $1.25 that analysts had expected. The shares moved up 1.67% in the following session.
Across the 6 reports in our data, the company beat estimates in 5. Even so, the stock fell in the first session after 1 of those 5 beats. Looking ahead, analysts expect EPS of $10.05 this fiscal year and $11.34 next year, with the current year showing growth of 119.4%.
AZN's average daily move is 1.60%, and its beta against the S&P 500 is 0.21. The stock trades 20.06% below its 52-week high of $212.71. Insider sales over the last 18 months totalled $54K, while open-market purchases came to $11.7M. Sales are often planned in advance or made to cover tax on vesting shares, which makes them a weaker signal than buying.
AZN against the Healthcare sector
How AZN compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: AZN trades at a notable discount to sector peers (-20%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 14, 2025, AZN has gained 29.9% against a gain of 39.2% for XLV.
Performance against XLV
AZN and the Healthcare sector fund over the same days.
Revenue and earnings
How much AZN sells, and how much of it becomes profit.
Revenue growth: Revenue grew 8.6% in FY2025 to $58.7B, from $54.1B a year earlier.
Profit margin: The net margin was 17.4% in FY2025, up from 13.0% the year before.
Profitable: AZN earned $10.2B in FY2025.
Earnings reality check
Did AZN beat what analysts expected, and how did the stock react?
Earnings record: AZN beat the analyst estimate in 5 of the 6 reports in our data.
Market reaction: The stock fell in the first session after 1 of those 5 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 27, 2026after close | $1.25 | $1.32 | +5.60% | +1.67% | -6.88% |
| Apr 29, 2026after close | $1.27 | $1.29 | +1.57% | +1.17% | -0.15% |
| Jul 29, 2025after close | $0.88 | $0.79 | -10.23% | +3.53% | +0.68% |
| Apr 29, 2025after close | $1.12 | $1.25 | +11.61% | +0.11% | -2.02% |
| Feb 6, 2025after close | $1.04 | $1.05 | +0.96% | -0.51% | +2.89% |
| Nov 12, 2024after close | $1.03 | $1.04 | +0.97% | +0.15% | -2.13% |
As of October 27, 2026, AZN has beaten the analyst EPS estimate in 5 of the 6 reports in our data and fell in the first trading session after 1 of those beats; its latest report, on July 27, 2026, came in 5.60% above the estimate and the stock moved +1.67% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AZN AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 58.9, in neutral territory.RSI above 50 ›
An RSI of 58.9 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of AZN
The score, the reasoning behind it, and what could move the price next.
AZN is trading between its two moving averages. The price of $170.05 sits 5.71% below the 200-day average of $180.35, yet it is 3.90% above the 50-day average of $163.66. Holding 28% of its 52-week range, the stock is 10.84% above its 52-week low of $153.41. The 50-day average is 9.26% below the 200-day average, which means the longer-run structure has not turned up yet, even though the price has climbed back above the shorter average.
The short and long run point different ways: the price rose 2.08% over the past month, fell 1.41% over the past three months and rose 1.15% over the past year. On momentum, the 14-day RSI reads 58.9, in the neutral zone, with the MACD line positive.
Earnings beat ›
The July 27, 2026 report beat the EPS estimate by 5.60%, and the share price rose 1.67% in the first session after it.
Source: Earnings report, July 27, 2026New analyst coverage ›
CICC started coverage at Outperform on August 24, 2026.
Source: Analyst action, CICC, August 24, 2026
- Keep an eye on the two nearest levels: the 200-day SMA at $180.35 sits above the price, and the 20-day EMA at $165.83 sits below it.
- A 14-day RSI of 58.9 sits in the neutral zone, and the MACD line is positive. Readings above 70 or below 30 would signal stretched momentum.
- In the first session after the July 27, 2026 report, the share price went up 1.67%. Over the 6 reports in our data, AZN beat estimates in 5.
AZN sits in a mixed trend. The price is above its 50-day average of $163.66 but below its 200-day average of $180.35. If the price closes above the 200-day, both signals would point up. If it closes below the 50-day, both would point down. For now, the 20-day EMA ($165.83) sits beneath the price and the 200-day SMA ($180.35) sits above it.
The 14-day RSI of 58.9 places AZN in neutral territory, inside the 40 to 60 band.
Technical indicators
Momentum and trend for AZN, from its daily closes.
As of October 27, 2026, with AZN at $170.05, its 14-day RSI is 58.9 (neutral territory), its 50-day simple moving average is $163.66 and its 200-day is $180.35.
Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What AZN moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 27, 2026, AZN's 1-year correlation of daily returns is +0.21 with S&P 500 (SPY), +0.10 with Nasdaq 100 (QQQ), +0.05 with Bitcoin (BTC) and +0.08 with gold (XAU).
AZN price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
9 of 12 analysts rate it a buy or strong buy, 2 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $208.00 is 22.3% above the price.More buy ratings than three months ago ›
9 of 12 rate it a buy now, against 8 of 10 three months ago.
AZN Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 24, 2026 | CICC | Initiates | Outperform |
As of October 27, 2026, 12 Wall Street analysts cover AZN: 9 rate it a buy or strong buy, 2 a hold and 1 a sell or strong sell. Their 12-month price targets range from $158.00 to $240.00. The median AZN price target is $208.00, 22.3% above the price of $170.05.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
AZN trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
AZN trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from AZN's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much AZN tends to move, against the market and on its own.
AZN price history and drawdowns
AZN's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.60% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 26.4%, from August 2024 to November 2024, regained by November 2025.Most 1-year holds ended higher ›
87% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $34,664, against $42,015 in the S&P 500 (SPY).
AZN Drawdowns & Recovery
As of October 27, 2026, AZN's worst peak-to-trough fall over the last 10 years with dividends reinvested was -26.4% (August 2024 to November 2024); it regained that peak by November 2025, 12 months after the low, and 87% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into AZN in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: AZN trailed the S&P 500 over this period: $34,664 against $42,015.
A $10,000 investment in AZN in October 2016 would be worth about $34,664 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to AZN, and which have not.
Strongest month, February: an average of +4.24%, up in 6 of 10 years.
Weakest month, September: an average of -1.60%, up in 5 of 10 years.
This month, October: has averaged +1.02%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, AZN's strongest calendar month has been February (average +4.24%, up in 6 of 10 years) and its weakest September (average -1.60%, up in 5 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
AZN stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in AZN, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in AZN today could grow to about $13,759 by 2030 in the base case, with a 90th-percentile outcome near $26,363 and a 10th-percentile outcome around $7,181. The simulation models price only; at today's 1.87% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
AZN Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $234 for AZN by 2030 in the base case, from $170 today (1.4x over 4 years). The 10th-percentile path ends near $122. These are outcomes of a Monte Carlo simulation run on AZN's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $133 | $184 | $255 | |
| 2028 | $126 | $199 | $316 | |
| 2029 | $123 | $216 | $379 | |
| 2030 | $122 | $234 | $448 |
Method: a lognormal simulation of AZN's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
AZN insider trading
What the people running the company have bought and sold.
AZN insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider buying: Insiders bought $11.7M on the open market and sold $54K.
As of October 27, 2026, AZN insiders reported 1 open-market sale worth $54K and 3 open-market purchases worth $11.7M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Demare (Michel)
|
Buy | 2.5K | $408.9K |
| Sep 14, 2026 | Sarin (Aradhana M.D.)
|
Grant | 73 | - |
| Sep 14, 2026 | Soriot (Pascal)
|
Buy | 60.0K | $9.8M |
| Aug 17, 2026 | Sarin (Aradhana M.D.)
|
Grant | 11.1K | - |
| May 14, 2026 | Soriot (Pascal)
|
Grant | 18.4K | - |
| Mar 5, 2026 | Soriot (Pascal)
|
Grant | 101.5K | - |
| Mar 4, 2026 | Sarin (Aradhana M.D.)
|
Grant | 4.9K | - |
| Mar 4, 2026 | Soriot (Pascal)
|
Grant | 15.0K | - |
| Jan 31, 2026 | BlackRock Financial Management, Inc.
|
Other | 0 | - |
| Jan 31, 2026 | Investor AB
|
Other | 0 | - |
| Dec 31, 2025 | Ashley (Euan)
|
Other | 0 | - |
| Dec 31, 2025 | BlackRock Financial Management, Inc.
|
Other | 0 | - |
| Dec 31, 2025 | Broadley (Philip)
|
Other | 0 | - |
| Dec 31, 2025 | Conix (Birgit)
|
Other | 0 | - |
| Dec 31, 2025 | Demare (Michel)
|
Other | 0 | - |
| Dec 31, 2025 | Eldracher (Deborah DiSanzo)
|
Other | 0 | - |
| Dec 31, 2025 | Investor AB
|
Other | 0 | - |
| Dec 31, 2025 | Knudsen (Karen)
|
Other | 0 | - |
| Dec 31, 2025 | Manz (Anna)
|
Other | 0 | - |
| Dec 31, 2025 | McCoy (Sherilyn S)
|
Other | 0 | - |
| Dec 31, 2025 | Rahman (Nazneen)
|
Other | 0 | - |
| Dec 31, 2025 | Rummelt (Andreas)
|
Other | 0 | - |
| Dec 31, 2025 | Sarin (Aradhana M.D.)
|
Other | 0 | - |
| Dec 31, 2025 | Soriot (Pascal)
|
Other | 0 | - |
| Dec 31, 2025 | Wallenberg (Marcus)
|
Other | 0 | - |
| Dec 18, 2025 | Rahman (Nazneen)
|
Sell | 297 | $53.6K |
| Dec 2, 2025 | The Capital Group Companies, Inc.
|
Grant | 1.0M | - |
| Nov 13, 2025 | The Capital Group Companies, Inc.
|
Grant | 2.8M | - |
| Nov 7, 2025 | Soriot (Pascal)
|
Grant | 249.9K | - |
| Aug 22, 2025 | The Capital Group Companies, Inc.
|
Grant | 183.5K | - |
| Aug 19, 2025 | The Capital Group Companies, Inc.
|
Grant | 516.2K | - |
| Aug 14, 2025 | Sarin (Aradhana M.D.)
|
Buy | 9.6K | $1.5M |
| Aug 13, 2025 | The Capital Group Companies, Inc.
|
Grant | 431.2K | - |
| Aug 8, 2025 | The Capital Group Companies, Inc.
|
Grant | 1.3M | - |
| May 21, 2025 | Soriot (Pascal)
|
Grant | 9.0K | - |
Source: TwelveData, from reported insider filings
AZN stock forecast: questions people ask
Answered from the figures on this page, as of October 27, 2026.